Semaglutide vs AOD-9604: GLP-1 vs HGH Fragment for Weight Loss

Semaglutide and AOD-9604 are both used for fat loss, but comparing them is somewhat like comparing a pharmaceutical-grade proven drug to a research peptide with limited clinical evidence—they're in genuinely different categories. Understanding what each does, what the evidence actually shows, and what the practical tradeoffs are requires clarity about mechanism, regulatory status, and realistic expectations.

What each compound is

Semaglutide (brand names: Ozempic, Wegovy, Rybelsus) is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone naturally released from the gut in response to food. It promotes insulin secretion, suppresses glucagon, slows gastric emptying, and—critically—reduces appetite through central nervous system effects in the hypothalamus and brainstem. Semaglutide is a long-acting synthetic analog of GLP-1 with a half-life of approximately one week, making weekly injections (or daily oral dosing with Rybelsus) practical.

AOD-9604 (Anti-Obesity Drug-9604) is a modified fragment of the human growth hormone molecule—specifically residues 176–191 of the HGH sequence with a tyrosine at the N-terminus added. It was developed by Monash University with the theory that this fragment contained HGH's lipolytic (fat-releasing) properties without its growth-promoting and insulin-desensitizing effects. It was researched as an anti-obesity drug in the early 2000s.

Mechanism of action

Semaglutide's fat loss mechanism:

1. Reduces appetite through hypothalamic GLP-1 receptors—users eat significantly less
2. Slows gastric emptying—food stays in the stomach longer, prolonging satiety
3. Reduces food reward/craving through central nervous system effects
4. Improves insulin sensitivity, shifting fuel metabolism toward fat oxidation
5. Modest direct lipolytic effects at higher doses

Semaglutide primarily works by reducing caloric intake. The weight loss it produces is largely explained by less eating, not by directly burning more fat or accelerating metabolism.

AOD-9604's proposed fat loss mechanism:

1. Stimulates lipolysis (fat breakdown) by binding to the beta-3 adrenergic receptor (proposed)
2. Inhibits lipogenesis (new fat creation)
3. Proposed to mimic HGH's lipolytic effects without raising IGF-1 or affecting blood sugar
4. Does NOT stimulate the growth hormone receptor or raise IGF-1

AOD-9604 was designed to work directly on fat cells—stimulating breakdown and inhibiting accumulation without the metabolic effects of full-length HGH.

The evidence gap

This is where the comparison becomes starkly asymmetric:

Semaglutide evidence:

• Multiple Phase 3 RCTs with thousands of participants
• STEP trials (obesity): 15–17% body weight loss vs. ~2% placebo over 68 weeks at 2.4 mg/week
• SUSTAIN trials (type 2 diabetes): Robust glycemic, cardiovascular, and weight loss data
• FDA-approved for weight management (Wegovy, 2021) and type 2 diabetes (Ozempic, 2017)
• Cardiovascular outcome trials showing mortality benefit in high-risk populations

AOD-9604 evidence:

• Phase 1 and 2 clinical trials conducted in early 2000s (METAOD studies): showed safety profile and some fat loss signals in obese adults
• Phase 3 trial failed to reach primary endpoint—the trial did not demonstrate statistically significant weight loss vs. placebo in the primary analysis
• Never received FDA approval for any indication
• More recent research: limited; primarily animal studies and mechanistic work

The failed Phase 3 trial is the critical fact about AOD-9604. Despite promising Phase 2 data, the drug did not demonstrate sufficient efficacy for FDA approval. The compound has since been used by the research peptide and biohacker community, but the regulatory and clinical evidence doesn't support the same confidence as semaglutide.

Regulatory status

| | Semaglutide | AOD-9604 | |---|---|---| | FDA approval | Yes (Ozempic, Wegovy, Rybelsus) | No | | Controlled substance | No | No | | Prescribability | Prescription required | Available as research peptide | | Compounding status | Complex (FDA scrutiny of compounding) | Available through compounding pharmacies | | TGA (Australia) approval | Approved | Not approved |

AOD-9604 received GRAS (Generally Recognized as Safe) designation from the FDA as a food ingredient, which is sometimes misrepresented as FDA approval for weight loss. GRAS means the ingredient is considered safe when used as a food additive—it does not mean it's approved as a drug for weight loss.

Side effect comparison

Semaglutide side effects:

• Nausea, vomiting, diarrhea: Very common, especially during dose escalation (affects 30–40% of users to some degree)
• Constipation: Common
• Fatigue: Occasional
• Pancreatitis: Rare but serious; boxed warning
• Thyroid C-cell tumor: Rodent data; FDA warning; not confirmed in humans but monitoring recommended
• Muscle loss: Significant concern—weight lost on GLP-1 agonists includes substantial lean mass. High protein intake and resistance training are essential to preserve muscle
• Gastroparesis: Rare serious complication; delayed gastric emptying can become pathological
• "Ozempic face": Rapid fat loss from facial fat with retained skin laxity

AOD-9604 side effects:

• Injection site reactions: Mild
• Headache: Occasional
• GI discomfort: Occasional
• No significant metabolic effects documented (doesn't affect blood sugar, doesn't raise IGF-1)
• Long-term safety: Less characterized than semaglutide given limited clinical data

AOD-9604's safety profile appears relatively benign in the data that exists. The absence of IGF-1 elevation or glucose effects is one of its theoretical advantages over full-length HGH as a lipolytic agent.

Cost comparison

| Option | Monthly Cost | |---|---| | Semaglutide (Ozempic, brand) | $800–$1,000 without insurance | | Semaglutide (Wegovy, brand) | $1,300–$1,600 without insurance | | Semaglutide (compounded) | $200–$400 | | AOD-9604 (research peptide vendor) | $50–$150 | | AOD-9604 (compounded pharmacy) | $100–$200 |

The cost of branded semaglutide without insurance has made compounded semaglutide a major market. FDA restrictions on compounded semaglutide have created significant access complications—the regulatory situation as of 2026 is evolving, with FDA having restricted compounding from some suppliers while allowing others. AOD-9604 is dramatically cheaper and more accessible.

Weight loss: realistic expectations

Semaglutide at 2.4 mg/week (Wegovy dose): Average ~15% body weight loss over 68 weeks in clinical trials. This is among the most significant pharmaceutical weight loss effects outside of bariatric surgery.

AOD-9604: The failed Phase 3 trial means we don't have a reliable estimate of average weight loss in a large population. Phase 2 data and anecdotal reports suggest modest fat loss effects, potentially more visible in abdominal fat specifically. Some users report meaningful results; others report none. The absence of clear clinical efficacy data makes this impossible to predict reliably.

When AOD-9604 might still be chosen

Despite the evidence disparity, AOD-9604 has specific contexts where it may be chosen:

• Patients who cannot tolerate semaglutide's GI side effects
• Those who want a lipolytic agent without appetite suppression (semaglutide's muscle loss risk from caloric restriction is a concern for body composition goals)
• When cost is prohibitive for semaglutide
• As an adjunct to other fat loss approaches rather than a primary agent
• Specifically targeting abdominal/visceral fat (the original research focus)

For a comprehensive look at AOD-9604 specifically, see the AOD-9604 peptide guide. For the broader GLP-1 peptide landscape, see the GLP-1 peptides guide.

The honest comparison

Semaglutide is one of the most effective pharmaceutical weight loss tools ever developed, with clinical trial data demonstrating effects that were previously only achievable with surgery. Its side effects are real and the muscle loss concern is underappreciated, but the efficacy evidence is unambiguous.

AOD-9604 is a research peptide with a plausible mechanism, an acceptable safety profile, failed Phase 3 efficacy data, and a much cheaper price. It may work for some people. It may not work at all for others. The honest evidence-based assessment is that AOD-9604 should not be compared to semaglutide as a peer—the evidence levels aren't equivalent.

The bottom line

Semaglutide is categorically superior to AOD-9604 for weight loss based on clinical evidence. If weight loss is the primary goal, semaglutide (at appropriate doses with medical supervision) produces predictably significant results. AOD-9604's niche is as a lower-cost, injection-based research option for people who specifically want fat mobilization without appetite suppression, can't access or tolerate semaglutide, or are exploring it as an adjunct rather than a primary weight loss agent. Approach AOD-9604 with realistic expectations calibrated to its failed Phase 3 trial.

---

Frequently Asked Questions

Q: Does AOD-9604 actually work for fat loss? The honest answer is: probably to some degree in some people, but the evidence is insufficient to characterize average efficacy reliably. The Phase 2 trials showed signals; Phase 3 failed to meet its primary endpoint. Anecdotal reports are mixed—some users report meaningful abdominal fat reduction, others see no effect. Without reliable Phase 3 data, you're essentially experimenting.

Q: Does AOD-9604 raise IGF-1 or HGH? No—this is its key advantage over full-length HGH. AOD-9604 is a HGH fragment specifically designed to lack the growth-promoting effects of full HGH. It does not meaningfully raise IGF-1 or interact with the growth hormone receptor in the same way as full HGH. Blood sugar and IGF-1 appear unaffected at standard doses.

Q: How does semaglutide compare to tirzepatide for weight loss? Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1/GIP receptor agonist with even more impressive weight loss data than semaglutide—the SURMOUNT-1 trial showed ~20–22% body weight loss vs. semaglutide's ~15% in STEP-1. For the detailed comparison, see the semaglutide vs tirzepatide guide.

Q: Is compounded semaglutide still available? As of 2026, the regulatory status of compounded semaglutide in the US is subject to ongoing FDA activity. The FDA declared semaglutide no longer in shortage, which restricts bulk-powder compounding; however, FDA-registered compounding pharmacies using approved drug products may still be able to compound under specific conditions. Verify current status with a healthcare provider—this situation is actively evolving.

Q: Can you use semaglutide and AOD-9604 together? There's no known pharmacological interaction. Some practitioners use AOD-9604 alongside lower-dose semaglutide with the idea that AOD-9604 provides direct lipolysis while semaglutide addresses appetite. This is speculative combination use without clinical evidence, and the additive cost and injection burden should be weighed against uncertain additional benefit.

---

Track your fat loss protocol and body composition progress with Optimize.